益赛普柳氮磺砒碇治疗强直性脊柱炎对照研究

目的研究益赛普对强直性脊柱炎(AS)的疗效,并与柳氮磺砒啶(SSZ)进行对照。方法60例活动性AS患者分别用益赛普(25mg/周)及柳氮磺砒碇(2.0/日)治疗,疗程24周,对两药在12、24周时疗效及观察指标进行评估。结果益赛普在12、24周时的有效率分别为86.7%,93.3%,柳氮磺吡啶为70.0%。显示益赛普能显著改善临床实验观察指标,耐受性与柳氮磺吡啶相似。结论益赛普为一新的有效的治疗AS的药物,且较安全。     

短期益赛普与甲氨蝶呤、环磷酰胺联合治疗类风湿关节炎的有效性研究

目的:探讨短期使用重组人型肿瘤坏死因子受体-抗体融合蛋白(rhTNFR:Fc,益赛普)与甲氨蝶呤(MTX)、环磷酰胺(CTX)联合治疗类风湿关节炎(RA)的疗效。方法:将84例患者随机分为实验组和对照组,仅有56例患者完成了本实验。实验组给予益赛普皮下注射治疗3个月,每周2次,每次25 mg;同时给予MTX治疗,每周1次,每次7.5~15 mg;CTX每3周1次,每次200 mg,3个月后给予空白模拟益赛普,继续接受MTX和CTX维持治疗。对照组给予益赛普皮下注射治疗,剂量及方法同实验组,同时给予空白模拟MTX和CTX对照,疗程为1年,在2周、4周、8周、12周、36周、52周评价并记录疗效相关指标。结果:实验组和对照组在ACR20,ACR70均较入组时有明显改善;但两组差异无显著性(P>0.05)。结论:短期益赛普与甲氨蝶呤、环磷酰胺联合治疗RA,可以减少益赛普的疗程,具有较好的疗效。     

重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗强直性脊柱炎的减量探索

目的探索一种经济、有效、安全的强直性脊柱炎(AS)患者应用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(益赛普)的减量方法。方法对入选的48例活动期AS患者随机分为A、B两组,进行1年的疗效观察。两组患者均接受益赛普治疗,初始剂量为25mg每周2次皮下注射,当疾病得到缓解(BASDAI<2;ESR男<15mm/h,女<20mm/h;CRP<0.8mg/dl;PLT<300×109/L),即将益赛普每隔2个月逐渐减量。如果减量使患者症状加重或ESR、CRP、PLT计数等炎性指标反弹至异常水平,则将益赛普重新调回前一个剂量,并于下次复查时评估以确定益赛普的剂量。A组患者同时接受柳氮磺吡啶(SSZ)口服治疗,初始剂量为0.25tid,第2周增至0.5bid,第3周增至0.75bid,第4周增至1.0bid维持至第24周。结果两组患者前2个月均使用推荐剂量的益赛普即25mg每周2次皮下注射,均取得令人满意的疗效,起效快,缓解率高,组间差别无统计学意义。病情获得缓解的病例从第3个月起减量至25mg每周1次,至第4个月末评估疗效,达到ASAS20的百分数A组明显高于B组,且差异具有统计学意义(P<0.05)。随着用药间隔逐渐延长,两组间的差距越来越大。当益赛普减量至25mg每2周1次后,组间差别更是达到P<0.01。结论 SSZ联合益赛普治疗AS可取得较高的疾病缓解率或低疾病活动状态,可明显延长益赛普的用药间隔。     

血常规检测在肛周脓肿疾病中的检测意义

目的探讨血常规检测在肛周脓肿疾病中的应用价值。方法选取2016年12月至2018年12月医院收治的96例肛周脓肿疾病患者作为观察组,另选取同期96名健康体检者作为对照组,两组受检者均行血常规检验,包括红细胞计数、白细胞计数、中性粒细胞百分比、血红蛋白及血小板等,比较两组血常规检测结果,并比较不同分期肛周脓肿疾病患者血常规检测结果。结果观察组白细胞计数、中性粒细胞百分比及血小板水平均显著高于对照组(P <0.05);观察组脓肿形成期白细胞计数、中性粒细胞百分比、血小板水平显著高于瘘管形成期和急性炎症期(P <0.05);观察组瘘管形成期白细胞计数、血小板水平显著高于急性炎症期(P <0.05)。结论在肛周脓肿疾病的临床诊断中,加强血常规检测有助于对疾病的发生及发展程度进行判断,其中脓肿形成期白细胞计数、中性粒细胞百分比水平偏高可作为制订治疗方案的可靠依据。     

益赛普、柳氮磺砒碇治疗强直性脊柱炎对照研究

目的 通过与柳氮磺砒啶（SSZ）进行对照,研究益赛普对强直性脊柱炎（AS）的疗效.方法 选取处于活动期的AS患者40例,分别给予益赛普（50 mg/周）及柳氮磺砒碇（2.0g/日）进行治疗,总疗程为24周,对两药在12、24周时疗效及观察指标进行评估.结果 益赛普在12、24周时的有效率分别为90.0%,95.0%,柳氮磺吡啶都为70.0%.显示益赛普能显著改善临床实验观察指标（P〈0.05）,耐受性与柳氮磺吡啶差异无显著性（P〉0.5）. 结论益赛普是一种新型有效且安全的治疗AS的药物.     

依托考昔与注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对患者强直性脊柱炎的疗效与安全性评价

目的:评价依托考昔与重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白注射剂(益赛普)联用患者难治性强直性脊柱炎(AS)的疗效与安全性。方法:选取2012年1月—2015年12月间收治的AS患者66例,采用随机数字表法将其分为对照组33例和治疗组33例;对照组患者给予益赛治疗,治疗组在对照组治疗基础上加用依托考昔治疗;治疗后第0、2、6、12周4个时间点评价两组患者临床疗效的评分值、及实验室检查项目测得值的变化情况和不良反应的发生率。结果:两组患者巴斯强直性脊柱炎病情活动指数、活动指数(BASDAI)、总评分值、脊柱痛和超敏C-反应蛋白(Hs-CRP)与治疗后第2、6、12周时均较同组治疗前有显著下降(P<0.05),但第6、12周时均低于治疗前(P<0.05);治疗2周治疗组患者各项指标均低于对照组及同组治疗前(P<0.05)。结论:采用依托考昔与益赛普治疗难治性AS患者起效较快,疗效较确切,安全性较好。     

血常规指标对急性白血病初诊患者的临床诊断价值

目的 评价针对急性白血病初诊患者进行血常规指标检测的价值,为急性白血病初诊患者的临床诊断工作提供参考,在有效诊断的基础上促进白血病患者的治疗预后。方法 选取85例急性白血病初诊患者作为研究组,同期85例体检健康者作为对照组。分析研究组患者血细胞数目异常情况。比较两组白细胞、红细胞、血小板、中性粒细胞比率、淋巴细胞比率、单核细胞比率。结果 研究组85例患者中,急性髓细胞性白血病患者65例(76.47%)、急性淋巴细胞白血病患者20例(23.53%)。研究组白细胞水平为(48.78±6.55)×10^9/L、红细胞水平为(2.86±0.55)×10^12/L、血小板水平为(60.06±18.80)×10^9/L、中性粒细胞比率为(19.08±5.02)%、淋巴细胞比率为(53.58±5.55)%、单核细胞比率为(33.58±6.05)%,对照组白细胞水平为(5.75±1.40)×10^9/L、红细胞水平为(4.80±0.45)×10^12/L、血小板水平为(175.50±30.50)×10^9/L、中性粒细胞比率为(59.05±5.55)%、淋巴细胞比率为(28.20±3.03)%、单核细胞比率为(6.09±2.08)%,研究组白细胞水平、淋巴细胞比率、单核细胞比率均高于对照组,红细胞水平、血小板水平、中性粒细胞比率均低于对照组,差异均具有统计学意义(P<0.05)。结论 血常规指标用于急性白血病初筛中的价值高,在区别于健康人员的基础上为急性白血病的临床诊断、治疗工作提供参考。     

早产儿白细胞和血小板计数的动态变化及其影响因素

目的探究早产儿白细胞和血小板计数的动态变化及其影响因素。方法选择2015年3月至2017年9月我院分娩的早产儿432例为研究对象,根据胎儿出生时胎龄分为两组,分别为A组(胎龄≤32周),B组(胎龄33～37周),对比两组早产儿的白细胞计数与血小板计数,并对其影响因素进行分析。结果 B组白细胞总数、中性粒细胞、单核细胞、血小板计数明显高于A组,差异有统计学意义(P <0.05);而B组淋巴细胞、嗜酸性粒细胞明显低于A组,差异有统计学意义(P <0.05);两组嗜碱性粒细胞比较,差异无统计学差异(P> 0.05)。结论胎龄对早产儿的白细胞分类、总数和血小板计数均有不同程度的影响。     

急性期布氏杆菌病致反应性组织细胞增多症25例临床分析

目的探讨布氏杆菌病患者骨髓组织细胞的变化及意义。方法对25例急性期布氏杆菌病患者的血常规、骨髓常规检查及涂片染色镜检，并进行临床观察。结果25例患者外周血白细胞减少10例，血红蛋白减少6例，血小板减少9例，三系减少4例，出现异形淋巴细胞16例；骨髓组织细胞均不同程度增多，占3％－22％，其中正常组织细胞25例、淋巴样细胞7例、单核样细胞20例、异常组织细胞3例、吞噬性组织细胞23例，中性粒细胞碱性磷酸酶积分90～245。经治疗3周后所有患者血细胞计数恢复正常，但仍有12例可见异型淋巴细胞；10例患者复查骨髓常规，仍有1例组织细胞增多。结论骨髓组织细胞的变化对急性期布氏杆菌病的诊断及疗效判断有参考价值，但要注意与恶性组织细胞病相鉴别。而外周血异型淋巴细胞的消失较慢，不能作为判断疗效的标准。     

柳氮磺胺吡啶联合益赛普治疗强直性脊柱炎并骨质疏松的临床观察

目的探讨柳氮磺胺吡啶联合益赛普治疗强直性脊柱炎并骨质疏松的临床疗效。方法本研究于2011年1月至2012年12月对在我院接受治疗的强直性脊柱炎并骨质疏松按照随机数字表法随机分为研究组和对照组,其中对照组给予柳氮磺胺吡啶片联合沙利度胺片治疗,而研究组采用柳氮磺胺吡啶联合益赛普治疗,比较两组患者的临床治疗效果及不良反应。结果研究组患者治疗后BASFI(2.95±1.45)、BASDI(2.75±1.16)评分较本组治疗前明显改善[(5.26±2.72)、(5.63±1.30)](t=4.69、5.62,P<0.05)。两组患者治疗后25OHD3、BGP、CTX-I水平与治疗前比较均明显改善,其中研究组的改善程度明显优于对照组(t=3.57、4.85、2.98,P<0.05)。两组在治疗后腰椎、股骨颈的骨密度值均有不同程度升高(t=2.29、3.98、2.36、2.83,P<0.05)。两组均未出现严重不良反应,无肝肾损害不良反应。结论柳氮磺胺吡啶联合益赛普治疗强直性脊柱炎并骨质疏松可以有效增加骨生成,减少骨吸收,提高AS患者的骨密度,改善AS患者骨代谢。     

依那西普治疗强直性脊柱炎的短期安全性分析

目的：评价依那西普治疗活动性强直性脊柱炎（AS）的短期安全性。方法：本研究为随机、双盲、安慰剂对照研究。为期12周,双盲期和开放治疗期各6周。最终入组104例活动性的AS患者,对照组和试验组各52例,分别于第6周和第12周对用药后的不良反应进行记录和评价。结果：第6周时不良反应发生率在对照组和试验组中分别为65．4％和69．2％,无统计差异;绝大部分为轻度注射部位反应和上呼吸道感染,经12周安全性观察无严重感染和严重不良事件发生。结论：依那西普治疗活动性AS安全性好,受试者可良好耐受。     

英夫利昔单抗治疗强直性脊柱炎的疗效观察

目的：探讨英夫利昔单抗治疗强直性脊柱炎（AS）的效果及安全性。方法：将60例确诊为AS并符合应用生物制剂的患者以随机抽样法分为对照组和观察组各30例,对照组患者在口服甲氨蝶呤的基础上应用柳氮磺胺吡啶等改善病情的药物;观察组患者在口服甲氨蝶呤的基础上联合应用英夫利昔单抗。观察2组患者治疗12周后的效果及治疗6、12周时的临床和实验室指标及不良反应发生情况。结果：治疗12周后,观察组患者疗效明显优于对照组（P〈0．05）。治疗6、12周后,观察组患者的Bath强直性脊柱炎病情活动指数评分（BASDAI）、Bath强直性脊柱炎功能指数（BASFI）、脊柱痛、晨僵、胸廓扩张度、C反应蛋白（CRP）、细胞沉降率（ESR）、腰椎活动度试验（Schober）等指标均明显优于治疗前,且与对照组比较,差异具有统计学意义（P〈O．05）;治疗6周后,对照组患者晨僵、ESR、BASFI较治疗前有显著改善（P〈0．05）,治疗12周后,对照组患者除血小板计数（PLT）、白细胞计数（WBC）、心率（HR）等指标外,其他指标较治疗前有明显改善（P〈0．05）。治疗6、12周后,2组患者的PLT、WBC下降,较治疗前均有显著差异（P〈0．05）,但2组间比较差异无统计学意义（P〉0．05）;2组患者治疗前后HR无明显变化（P〉0．05）;2组均未见明显不良反应。结论：英夫利昔单抗治疗AS,可以更早期地达到诱导、缓解病情的目的,较为安全、有效。     

Restorative effect of muroctasin on leukopenia caused by anticancer chemotherapy in lung cancer. Comparative study by envelope method

N2-[(N-Acetylmuramoyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-lysine (MDP-Lys(L18), muroctasin), a derivative of muramyl dipeptide, is known to have the activity to augment the number of white blood cells (WBC) via colony-stimulating factor. Muroctasin has been expected to be applied to leukopenia caused by anticancer chemotherapy. When WBC decreased to less than or equal to 3,000/mm3 after the 1st course of chemotherapy, 131 patients with lung cancer, who were previously classified by the combination regimens of chemotherapy, were enrolled in the study and randomized into 3 groups, 200 micrograms (H), 100 micrograms (L) and untreated control (C) groups. The patients were then subcutaneously treated once daily for 6 consecutive days. WBC and its differential count were measured on Days 4, 7 and 15 after commencement of the study. WBCs in H and L groups were recovered greater than in C group. In WBC differential count, the recovery of neutrophil was prominent in muroctasin treated groups. The portion of immature neutrophil in the bone marrow was also increased by muroctasin treatment. A restorative effect on WBC and neutrophil counts was also confirmed only in the second course of H group. On the other hand, fever and pain in the injected site as side effects were common in the H group and L group in both of courses. In this study, the usefulness of muroctasin in leukopenia was suggested when administered at dosages of 200 micrograms for 6 days.     

Hematological response to the new synthetic muramyl dipeptide derivative muroctasin after chemotherapy in patients with malignant lymphoma. A randomized crossover trial

A randomized crossover trial was performed in 20 patients receiving chemotherapy for malignant lymphoma. N2-[(N-acetylmuramoyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-lysine (MDP-Lys(L18), muroctasin) at a dose of 200 micrograms was subcutaneously administered after one of two cycles of the same protocol. The administration was started on day 4 after the start of chemotherapy and continued for 10 days. The mean length from the start of chemotherapy to nadir of white blood cell (WBC) was not significantly different between the control and muroctasin cycles. The mean WBC and neutrophil counts at nadir of the control cycle were significantly lower than those at the same point of muroctasin cycle, respectively. A positive effect of muroctasin cycle, defined as WBC count at nadir being increased by 1,000/mm3, WBC count being increased by 1,000/mm3 on two points examined after nadir, or faster reach to nadir and faster recovery to normal range of WBC than in the control cycle, was observed in 7 (35%) of 20 patients. On the other hand, only one (5%) patient showed a superiority of the control cycle over the muroctasin cycle. Toxic effects of muroctasin were observed in 34.8% of patients, but were tolerable for most patients. These results show that muroctasin has a clinical efficacy in the restoration of leukopenia after chemotherapy.     

依那西普治疗强直性脊柱炎的安全性研究

目的：观察依那西普治疗强直性脊柱炎（ankylosing spondylitis，AS）出现的不良反应。方法：本研究采用随机、双盲、安慰剂平行对照的方案，2005年4月至2006年1月对52例活动性AS患者随机分入依那西普组及安慰剂组，每组患者各26例，依那西普组平均年龄（27．7±8．5）岁，安慰剂组平均年龄（29．7±8．1）岁。整个研究持续12周，前6周为双盲治疗期，后6周为开放治疗期。在双盲期，依那西普组给予依那西普25mg／次，皮下注射，每周2次，连续用药6周；安慰剂组给予非活性物质25mg／次，皮下注射，每周2次，连续用药6周。开放治疗期，2组均使用依那西普25mg／次，皮下注射，每周2次，连续用药6周。于第0、1、2、4、6、7、8、10、12周进行血常规检查，观察分析注射部位皮肤反应、其他的皮肤及附属器官的反应、感染的发生情况、血液系统反应、肝酶水平、自身抗体反应及其他不良反应。结果：依那西普组和安慰剂组的不良反应发生率分别为23％和38％。差异无统计学意义（P〉0．05）；无严重不良事件发生。双盲期内依那西普组有26．9％的患者出现注射部位皮肤红肿、硬结和瘙痒反应，安慰剂组无l例出现该反应，2组差别有统计学意义（P〈0．05）。试验期间注射部位皮肤反应的发生率为34．6％。双盲期依那西普组有6例患者（23．1％）出现中性粒细胞减少，而安慰剂组无1例发生该反应，2组之间差异有统计学意义（P〈0．05）。依那西普组和安慰组的其他不良反应如上呼吸道感染（分别为5例与7例）、皮肤及附属器官反应（分别为6例和3例）、肝酶升高（分别为5例和8例）等，差异均无统计学意义（均P〉0．05）。结论：依那西普是一种较为安全的治疗AS的药物。     

Can monocyte/HDL show inflammatory activity of isotretinoin treatment in acne patients?

Abstract

Aim: There are reports that isotretinoin causes some important diseases such as teratogenicity, inflammatory bowel disease and sacroiliitis by triggering inflammation. (Monocyte/HDL (high density lipoprotein) ratio) MHR is closely related to inflammation and is thought to be an indicator of atherosclerotic development. We aimed to investigate how isotretinoin (ISO) affects the immunoinflammatory response in acne patients.

Materials and Methods: In this study, 116 nodulocystic acne patients who received ISO treatment for at least three months were evaluated retrospectively. ISO treatment was given to patients at a dose of 0.5–1?mg/kg. Pre-treatment and post-treatment white blood cell (WBC), neutrophil, lymphocyte, monocyte, platelet, mean platelet volume (MPV), platelet, plateletcrit, platelet distribution width (PDW), neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), total cholesterol, LDL cholesterol, triglyceride, HDL cholesterol and MHR were evaluated.

Results: MPV and MHR values were significantly increased after 3?month treatment (p?<?0.05). There was no significant change in NLR and PLR values (p?>?0.05). There was a significant decrease in neutrophil count (p?<?0.05). There were no significant changes in WBC, lymphocyte, monocyte, platelet, plateletcrit values (p?>?0.05). Total cholesterol, LDL cholesterol and triglyceride levels were significantly increased after three months of treatment (p?<?0.05). HDL cholesterol levels decreased significantly after three months of treatment (p?<?0.05).

Conclusion: We concluded that ISO treatment may trigger inflammation due to the increase in MPV and MHR value. MHR can show inflammation after ISO treatment.     

Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides

The therapeutic options for patients suffering from severe forms of spondyloarthritis (SpA) have been rather limited in recent decades. There is now accumulating evidence that anti-TNF therapy is highly effective in SpA, especially in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Based on the data recently published on what is now several hundred AS and PsA patients, this treatment seems to be even more effective than the same therapy in rheumatoid arthritis (RA). The anti-TNF-α agents currently available, infliximab (Remicade^®; Centocor), etanercept (Enbrel^®; Amgen) and adalimumab (Humira?; Abbott), are approved for the treatment of RA in the US; infliximab and etanercept are approved in Europe. The situation in SpA is different to RA because there is an unmet medical need, especially in AS, since no therapies with disease-controlling antirheumatic drugs are available for severely affected patients, especially with spinal disease. Thus, TNF blockers might even be considered as first-line immunosuppressive agents in patients with active AS and PsA who are not sufficiently treated by non-steroidal anti-inflammatory drugs and sulfasalazine, if peripheral arthritis is present. For infliximab, a dosage of 5 mg/kg at intervals between 6 and 12 weeks was necessary to constantly suppress disease activity; this is also a major aim of long-term treatment. No dose-finding studies have yet been performed. The standard dose of etanercept is 25 mg s.c. twice-weekly. No studies on adalimumab (standard RA dose 20 – 40 mg s.c. every 2 weeks) have yet been conducted in SpA. The efficacy of etanercept was first demonstrated in PsA and etanercept is now approved for this indication. A double-blind study has also been performed in AS, with similarly clearcut efficacy. There is preliminary evidence that both agents do also work in other SpA such as undifferentiated SpA. Infliximab has recently been approved for short-term treatment of severe uncontrolled AS; the approval for etanercept is pending. Studies should be performed to document the long-term efficacy of this treatment. There is hope that ankylosis might be preventable but it remains to be shown whether patients benefit from long-term anti-TNF therapy and whether radiological progression and ankylosis can be stopped. Severe adverse events have remained rare. Complicated infections including tuberculosis have been reported. Tuberculosis can be mostly prevented if patients are checked for previous contact with tuberculosis. Currently, the benefits of anti-TNF therapy in AS seem to outweigh these shortcomings.     

Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides

The therapeutic options for patients suffering from severe forms of spondyloarthritis (SpA) have been rather limited in recent decades. There is now accumulating evidence that anti-TNF therapy is highly effective in SpA, especially in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Based on the data recently published on what is now several hundred AS and PsA patients, this treatment seems to be even more effective than the same therapy in rheumatoid arthritis (RA). The anti-TNF-alpha agents currently available, infliximab (Remicade); Centocor), etanercept (Enbrel); Amgen) and adalimumab (Humira; Abbott), are approved for the treatment of RA in the US; infliximab and etanercept are approved in Europe. The situation in SpA is different to RA because there is an unmet medical need, especially in AS, since no therapies with disease-controlling antirheumatic drugs are available for severely affected patients, especially with spinal disease. Thus, TNF blockers might even be considered as first-line immunosuppressive agents in patients with active AS and PsA who are not sufficiently treated by non-steroidal anti-inflammatory drugs and sulfasalazine, if peripheral arthritis is present. For infliximab, a dosage of 5 mg/kg at intervals between 6 and 12 weeks was necessary to constantly suppress disease activity; this is also a major aim of long-term treatment. No dose-finding studies have yet been performed. The standard dose of etanercept is 25 mg s.c. twice-weekly. No studies on adalimumab (standard RA dose 20 - 40 mg s.c. every 2 weeks) have yet been conducted in SpA. The efficacy of etanercept was first demonstrated in PsA and etanercept is now approved for this indication. A double-blind study has also been performed in AS, with similarly clearcut efficacy. There is preliminary evidence that both agents do also work in other SpA such as undifferentiated SpA. Infliximab has recently been approved for short-term treatment of severe uncontrolled AS; the approval for etanercept is pending. Studies should be performed to document the long-term efficacy of this treatment. There is hope that ankylosis might be preventable but it remains to be shown whether patients benefit from long-term anti-TNF therapy and whether radiological progression and ankylosis can be stopped. Severe adverse events have remained rare. Complicated infections including tuberculosis have been reported. Tuberculosis can be mostly prevented if patients are checked for previous contact with tuberculosis. Currently, the benefits of anti-TNF therapy in AS seem to outweigh these shortcomings.     

肿瘤坏死因子α拮抗剂联合中小剂量糖皮质激素治疗重症药疹2例并文献复习

目的:观察肿瘤坏死因子α（TNF-α）拮抗剂联合中小剂量糖皮质激素在重症药疹中的作用。方法:总结南京医科大学附属无锡第二人民医院2020年收治的2例重症药疹发病及转归。结果:（1）例1患者男,52岁,31 d前因右面部三叉神经痛口服卡马西平,发热、全身皮疹,白细胞、C反应蛋白（CRP）升高伴肝功能损害,诊断：Steve...